Financials in USD. Standardized financial statements.
A compact view of how Elite Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $84.04M | $56.63M | $34.16M | $32.26M | $25.38M | $17.99M | $7.57M | $7.46M | $9.64M | $12.50M |
| Revenue Growth? | +48.4% | +65.8% | +5.9% | +27.1% | +41.0% | +137.8% | +1.5% | -22.6% | -22.9% | 0.0% |
| Cost of Revenue? | $43.96M | $30.27M | $17.56M | $17.47M | $13.51M | $10.02M | $4.70M | $3.51M | $5.90M | $4.48M |
| Gross Profit? | $40.09M | $26.36M | $16.59M | $14.80M | $11.87M | $7.98M | $2.87M | $3.95M | $3.74M | $8.01M |
| Gross Margin? | +47.7% | +46.5% | +48.6% | +45.9% | +46.8% | +44.3% | +37.9% | +52.9% | +38.8% | +64.1% |
| Operating Expenses? | $20.49M | $15.57M | $12.92M | $9.72M | $9.76M | $10.26M | $12.03M | $13.00M | $11.10M | $16.33M |
| Operating Income? | $19.60M | $10.79M | $2.03B | $5.07M | $2.10M | -$2.29M | -$9.16M | -$9.05M | -$7.36M | -$8.32M |
| EBITDA? | $2.84M | $2.52M | $6.43M | $6.49M | $3.63M | -$371,876 | -$8.34M | -$3.40M | $2.88M | -$257,147 |
| Income Before Tax | -$52,140 | $463,092 | $3.99M | $7.16M | $4.14M | -$2.24M | -$9.96M | -$4.72M | $1.94M | -$1.20M |
| Income Tax Expense | $4.26M | -$19.65M | -$424.03M | -$1.74M | -$943,907 | $2,000 | -$427,464 | -$710,331 | -$1.63M | -$520,452 |
| Net Income? | -$4.31M | $20.11M | $4.41M | $8.90M | $5.09M | -$2.24M | -$9.28M | -$3.67M | $3.81M | -$683,012 |
| EPS? | $-0.00 | $0.02 | $4.35 | $0.01 | $0.01 | $-0.00 | $-0.01 | $-0.00 | $0.03 | $-0.00 |
| Diluted EPS? | $-0.00 | $0.02 | $4.35 | $0.01 | $0.01 | $-0.00 | $-0.01 | $-0.00 | $-0.01 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality